Comments to the Docket for FDA Proposed Guidance for Industry on Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease

View as PDF.

Public Citizen submits comments on the FDA’s proposed industry guidance for Treatment of Early Stage Alzheimer’s Disease, including its absence of discussion of the effectiveness of physical and mental exercise and a critique of the Guidance itself because it lacks a scientific basis for either accurately diagnosing or measuring the effects of treatment on people with such early disease.